The US Food and Drug Administration (FDA) has approved a reusable Bluetooth-enabled insulin pen and associated smartphone app for the treatment of type 1 diabetes.The device, which is manufactured by Companion Medical, is called InPen and it is expected to be launched on Apple iOS smartphones in 2017.The InPen system has been approved for use with Humalog, made by Eli Lilly, and Novolog, made by Novo Nordisk. Both of these are rapid-acting insulins.The device can track insulin doses automatically and send data to the paired app via Bluetooth. Then, a bolus calculator and automatic insulin-on-board allows users to receive these benefits from insulin pumping, without having to wear an insulin pump. This information can also be sent to healthcare providers and caregivers.
NOSTRA III Trial to Assess Efficacy and Safety of Ronopterin (VAS203) in the Treatment of Moderately to Severely Injured Traumatic Brain Injury Patientsvasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced that the first patient has been enrolled in to the NOSTRA III (NO Synthase in TRAumatic Brain Injury) trial - a phase III clinical trial assessing efficacy and safety of Ronopterin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain (TBI) injury patients.Traumatic brain injury (TBI) is the leading cause of death and disability among young adults and occurs when a sudden trauma causes damage to the brain. Every year, over 1,600,000 patients sustain a traumatic brain injury in the EU, and 70,000 of these die, with a further 100,000 being left disabled.
VMS Rehab Systems, Inc. reports on status of its BioPharmcor drug unit formulation development program
PRNewswire/ -- The Board of Directors of VMS Rehab Systems, Inc. reported today that the Company's generic drug unit, BioPharmcor BV has made significant progress over the past 18 months in its formulation development program of its first generic drug , tadalafil, a first line treatment for men suffering from Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH). The company has indicated that the results of BioPharmcor's drug formulation development program for tadalafil have produced a formulation and manufacturing process that is equivalent to the branded drug reference product in terms of its key quality physical and chemical attributes and also has similar drug release characteristics that are indicative of comparable in vivo performance.
FALL RIVER, Mass.--(BUSINESS WIRE)--WOUNDCHEK™ Laboratories announced today that WOUNDCHEK™ Protease Status, the world’s first point of care wound diagnostic for chronic wounds, has received market clearance from the Australian Therapeutic Goods Administration. Intermed Medical Pty Ltd has been appointed as distributor for the product in Australia and New Zealand.
New research released at European Respiratory Society (ERS) International Congress 2016 highlights the benefits of home non-invasive ventilation (NIV), with the potential to positively impact current practice and improve the lives of patients with COPD ResMed at-home COPD management portfolio now includes portable oxygen therapy, alongside home NIV and remote monitoring technology
Poxel to Present New Imeglimin and PXL770 Data at the 52nd European Association for the Study of Diabetes Annual Meeting
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that three abstracts have been accepted for presentations, which include two poster presentations and one oral presentation, at the 52nd European Association for the Study of Diabetes Annual meeting, to be held September 12th – 16th in Munich, Germany.
Vedanta Biosciences Granted Third U.S. Patent Covering Methods of Treating Infectious and Allergic Diseases with Bacterial Consortia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, pioneering the development of a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,433,652. The patent broadly covers methods of treating a variety of diseases including infectious and allergic diseases with mixtures of Clostridium live bacterial strains and further expands Vedanta Biosciences’ patent portfolio after the issuances of U.S. 9,415,079 and U.S. 9,421,230 in August and earlier issuances in Japan. The patents are exclusively licensed to Vedanta Biosciences under an agreement with the University of Tokyo and provide coverage through at least 2031.